{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:41:33Z","timestamp":1794429693676,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10613-x","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:27:25Z","timestamp":1753266445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review"],"prefix":"10.1038","volume":"15","author":[{"given":"Jun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"6","key":"10613_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.beem.2016.11.002","volume":"30","author":"A Chinoy","year":"2016","unstructured":"Chinoy, A. & Murray, P. G. Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract. Res. Clin. Endocrinol. Metab. 30 (6), 737\u2013747 (2016).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"1","key":"10613_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11154-020-09604-2","volume":"22","author":"MCS Boguszewski","year":"2021","unstructured":"Boguszewski, M. C. S. Growth hormone deficiency and replacement in children. Rev. Endocr. Metab. Disord. 22 (1), 101\u2013108 (2021).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"10613_CR3","doi-asserted-by":"publisher","unstructured":"Mameli, C. et al. Epidemiology of growth hormone deficiency in children and adolescents: a systematic review. Endocrine 85, 91\u201398 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03778-4.","DOI":"10.1007\/s12020-024-03778-4"},{"issue":"6","key":"10613_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"86","author":"A Grimberg","year":"2016","unstructured":"Grimberg, A. et al. Guidelines for growth hormone and Insulin-Like growth Factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary Insulin-Like growth Factor-I deficiency. Horm. Res. Paediatr. 86 (6), 361\u2013397 (2016).","journal-title":"Horm. Res. Paediatr."},{"issue":"6","key":"10613_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.beem.2016.11.005","volume":"30","author":"E Richmond","year":"2016","unstructured":"Richmond, E. & Rogol, A. D. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract. Res. Clin. Endocrinol. Metab. 30 (6), 749\u2013755 (2016).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10613_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ghir.2018.12.004","volume":"44","author":"PF Collett-Solberg","year":"2019","unstructured":"Collett-Solberg, P. F. et al. Growth hormone therapy in children; research and practice - A review. Growth Horm. IGF Res. 44, 20\u201332 (2019).","journal-title":"Growth Horm. IGF Res."},{"issue":"06","key":"10613_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1055\/a-1842-0724","volume":"54","author":"X Gao","year":"2022","unstructured":"Gao, X. et al. First clinical study on Long-Acting growth hormone therapy in children with Turner sydrome. Horm. Metab. Res. 54 (06), 389\u2013395 (2022).","journal-title":"Horm. Metab. Res."},{"issue":"10","key":"10613_CR8","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1007\/s00431-024-05719-9","volume":"183","author":"L Xie","year":"2024","unstructured":"Xie, L. et al. Effect of long-acting pegylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study. Eur. J. Pediatr. 183 (10), 4531\u20134539 (2024).","journal-title":"Eur. J. Pediatr."},{"issue":"10","key":"10613_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s12325-011-0063-8","volume":"28","author":"J L\u00f3pez-Siguero","year":"2011","unstructured":"L\u00f3pez-Siguero, J. et al. Long-term safety and efficacy of the Recombinant human growth hormone Omnitrope\u00ae in the treatment of Spanish growth hormone deficient children: results of a phase III study. Adv. Ther. 28 (10), 879\u2013893 (2011).","journal-title":"Adv. Ther."},{"key":"10613_CR10","doi-asserted-by":"publisher","first-page":"864058","DOI":"10.3389\/fphar.2022.864058","volume":"13","author":"J Li","year":"2022","unstructured":"Li, J. et al. Metabolomic differential compounds reflecting the clinical efficacy of polyethylene glycol Recombinant human growth hormone in the treatment of childhood growth hormone deficiency. Front. Pharmacol. 13, 864058 (2022).","journal-title":"Front. Pharmacol."},{"key":"10613_CR11","doi-asserted-by":"publisher","first-page":"790169","DOI":"10.3389\/fendo.2021.790169","volume":"12","author":"R Coutant","year":"2021","unstructured":"Coutant, R. et al. Yearly height gain is dependent on the truly received dose of growth hormone and the duration of periods of poor adherence: practical lessons from the French easypod\u2122 connect multicenter observational study. Front. Endocrinol. (Lausanne). 12, 790169 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10613_CR12","doi-asserted-by":"publisher","first-page":"980979","DOI":"10.3389\/fendo.2022.980979","volume":"13","author":"BS Miller","year":"2022","unstructured":"Miller, B. S. What do we do now that the long-acting growth hormone is here? Front. Endocrinol. (Lausanne). 13, 980979 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10613_CR13","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.1038\/s41598-024-58616-4","volume":"14","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis. Sci. Rep. 14 (1), 8061 (2024).","journal-title":"Sci. Rep."},{"issue":"7","key":"10613_CR14","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"CL Deal","year":"2022","unstructured":"Deal, C. L. et al. Efficacy and safety of weekly Somatrogon vs daily Somatropin in children with growth hormone deficiency: A phase 3 study. J. Clin. Endocrinol. Metab. 107 (7), e2717\u2013e2728 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10613_CR15","doi-asserted-by":"publisher","first-page":"955809","DOI":"10.3389\/fphar.2022.955809","volume":"13","author":"Z Jiang","year":"2022","unstructured":"Jiang, Z. et al. Short-term efficacy and safety of a lower dose of polyethylene glycol Recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study. Front. Pharmacol. 13, 955809 (2022).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10613_CR16","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.21037\/apm-20-871","volume":"10","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. The impact of pegylated Recombinant human growth hormone replacement therapy on glucose and lipid metabolism in children with growth hormone deficiency. Ann. Palliat. Med. 10 (2), 1809\u20131814 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"10613_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ghir.2018.01.004","volume":"40","author":"E Lundberg","year":"2018","unstructured":"Lundberg, E. et al. Broad variability in pharmacokinetics of GH following RhGH injections in children. Growth Horm. IGF Res. 40, 61\u201368 (2018).","journal-title":"Growth Horm. IGF Res."},{"key":"10613_CR18","doi-asserted-by":"publisher","first-page":"821588","DOI":"10.3389\/fendo.2022.821588","volume":"13","author":"W Wu","year":"2022","unstructured":"Wu, W. et al. PEGylated Recombinant human growth hormone Jintrolong(\u00ae) exhibits good Long-Term safety in Cynomolgus monkeys and human pediatric growth hormone deficiency patients. Front. Endocrinol. (Lausanne). 13, 821588 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10613_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1515\/jpem-2021-0735","volume":"35","author":"H Du","year":"2022","unstructured":"Du, H. et al. Evaluation of efficacy and safety of long-acting pegylated Recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 35 (4), 511\u2013517 (2022).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"2","key":"10613_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-16-0905","volume":"177","author":"X Luo","year":"2017","unstructured":"Luo, X. et al. Long-acting pegylated Recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur. J. Endocrinol. 177 (2), 195\u2013205 (2017).","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10613_CR21","first-page":"pEd000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston, M. et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst. Rev. 10 (10), pEd000142 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10613_CR22","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6 (7), e1000097 (2009).","journal-title":"PLoS Med."},{"key":"10613_CR23","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj 343, d5928 (2011).","journal-title":"Bmj"},{"issue":"9","key":"10613_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (9), 603\u2013605 (2010).","journal-title":"Eur. J. Epidemiol."},{"key":"10613_CR25","doi-asserted-by":"publisher","first-page":"p1438723","DOI":"10.1155\/2019\/1438723","volume":"2019","author":"Y Qiao","year":"2019","unstructured":"Qiao, Y. et al. Use of pegylated Recombinant human growth hormone in Chinese children with growth hormone deficiency: A 24-Month Follow-Up study. Int. J. Endocrinol. 2019, p1438723 (2019).","journal-title":"Int. J. Endocrinol."},{"key":"10613_CR26","doi-asserted-by":"publisher","first-page":"779365","DOI":"10.3389\/fendo.2021.779365","volume":"12","author":"C Sun","year":"2021","unstructured":"Sun, C. et al. Reduced effectiveness and comparable safety in biweekly vs. Weekly pegylated Recombinant human growth hormone for children with growth hormone deficiency: A phase IV Non-Inferiority threshold targeted trial. Front. Endocrinol. 12, 779365 (2021).","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10613_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1651-2227.2010.01994.x","volume":"100","author":"CL Wang","year":"2011","unstructured":"Wang, C. L. et al. Effects of short- and long-acting Recombinant human growth hormone (PEG-rhGH) on left ventricular function in children with growth hormone deficiency. Acta P\u00e6diatrica. 100 (1), 140\u2013142 (2011).","journal-title":"Acta P\u00e6diatrica"},{"key":"10613_CR28","doi-asserted-by":"publisher","unstructured":"Chen, W. J. & Zhang, J. A comparative study on efficacy of long- and short-term Recombinant growth hormones in pediatric patients with growth hormone deficiency. J. Clin. Experimental Med., 18(2),  171\u2013174 ( (2019). https:\/\/doi.org\/10.3969\/j.issn.1671-4695.2019.02.017.","DOI":"10.3969\/j.issn.1671-4695.2019.02.017"},{"issue":"7","key":"10613_CR29","first-page":"755","volume":"29","author":"NJ Wan","year":"2021","unstructured":"Wan, N. J. et al. Study on the eficacy and safety of long-acting growth hormones in treating pediatric growth hormone deficiency patients. Chin. J. Child. Health Care. 29 (7), 755\u2013758 (2021).","journal-title":"Chin. J. Child. Health Care"},{"issue":"8","key":"10613_CR30","first-page":"1079","volume":"29","author":"DH Yang","year":"2022","unstructured":"Yang, D. H. & Zhang, J. Impact of long -Acting Recombinant human growth hormone therapy on growth and IGF \u2013\u20091 level of children with growth hormone deficiency. Clin. Med. Eng. 29 (8), 1079\u20131080 (2022).","journal-title":"Clin. Med. Eng."},{"key":"10613_CR31","unstructured":"Li, J. & Liu, D. Y. Efficacy, Safety and Compliance of Phase IV Clinical Trial of PEG-rhGh in the Treatment of Children with GHD (ANHUI MEDICAL UNIVERSITY, 2020)."},{"issue":"2","key":"10613_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025649","volume":"36","author":"K Chaudhary","year":"2019","unstructured":"Chaudhary, K., Patel, M. M. & Mehta, P. J. Long-Acting injectables: current perspectives and future promise. Crit. Rev. Ther. Drug Carrier Syst. 36 (2), 137\u2013181 (2019).","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10613_CR33","doi-asserted-by":"crossref","unstructured":"Xie, L. et al. Effect of long-acting pegylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study. Eur. J. Pediatr. 183,  4531\u20134539 (2024).","DOI":"10.1007\/s00431-024-05719-9"},{"key":"10613_CR34","doi-asserted-by":"publisher","first-page":"106805","DOI":"10.1016\/j.phrs.2023.106805","volume":"193","author":"C Mameli","year":"2023","unstructured":"Mameli, C. et al. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis. Pharmacol. Res. 193, 106805 (2023).","journal-title":"Pharmacol. Res."},{"key":"10613_CR35","doi-asserted-by":"crossref","unstructured":"Luo, X. et al. Long-acting pegylated growth hormone in children with idiopathic short stature. Eur. J. Epidemiol  187(5), 709\u2013718  (2022).","DOI":"10.1530\/EJE-22-0449"},{"key":"10613_CR36","doi-asserted-by":"crossref","unstructured":"Miller, B. S., Blair, J. C. & Rasmussen, M. H. Weekly Somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J. Clin. Endocrinol. Metab   107(12), 3378\u20133388 (2022).","DOI":"10.1210\/clinem\/dgac513"},{"issue":"5","key":"10613_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/mp.54.5.311","volume":"54","author":"Z Laron","year":"2001","unstructured":"Laron, Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol. Pathol. 54 (5), 311\u2013316 (2001).","journal-title":"Mol. Pathol."},{"issue":"3","key":"10613_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1189\/jlb.0310158","volume":"88","author":"DJ Gow","year":"2010","unstructured":"Gow, D. J., Sester, D. P. & Hume, D. A. CSF-1, IGF-1, and the control of postnatal growth and development. J. Leukoc. Biol. 88 (3), 475\u2013481 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"10613_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000445173","volume":"47","author":"AR Nicholls","year":"2016","unstructured":"Nicholls, A. R. & Holt, R. I. Growth hormone and Insulin-Like growth Factor-1. Front. Horm. Res. 47, 101\u2013114 (2016).","journal-title":"Front. Horm. Res."},{"key":"10613_CR40","first-page":"13","volume":"10","author":"L Hou","year":"2016","unstructured":"Hou, L. et al. Comparative pharmacokinetics and pharmacodynamics of a pegylated Recombinant human growth hormone and daily Recombinant human growth hormone in growth hormone-deficient children. Drug Des. Devel Ther. 10, 13\u201321 (2016).","journal-title":"Drug Des. Devel Ther."},{"issue":"11","key":"10613_CR41","first-page":"3184","volume":"106","author":"PS Thornton","year":"2021","unstructured":"Thornton, P. S. et al. Weekly Lonapegsomatropin in Treatment-Na\u00efve children with growth hormone deficiency: the phase 3 height. Trial 106 (11), 3184\u20133195 (2021).","journal-title":"Trial"},{"issue":"8","key":"10613_CR42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/clinem\/dgad039","volume":"108","author":"L Hou","year":"2023","unstructured":"Hou, L. et al. Long-term pegylated GH for children with GH deficiency: A large, prospective, Real-world study. J. Clin. Endocrinol. Metab. 108 (8), 2078\u20132086 (2023).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10613-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:35:09Z","timestamp":1757273709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10613-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10613-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors assert that there are no conflicts of interest present.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"26746"}}